Search
Otelixizumab
go.drugbank.com/drugs/DB05496InvestigationalOtelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling.
KW-7158
go.drugbank.com/drugs/DB05498ExperimentalKW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity … The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion
NM-702
go.drugbank.com/drugs/DB05505InvestigationalIntermittent claudication is a major symptom of arteriosclerosis obliterans. … Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans.
Belnacasan
go.drugbank.com/drugs/DB05507InvestigationalVX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198).
Piclidenoson
go.drugbank.com/drugs/DB05511InvestigationalCF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors. CF101 is supplied as an oral drug and has an excellent sa...
QR-333
go.drugbank.com/drugs/DB05533InvestigationalQR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder … QR-333 has been investigated as a treatment for diabetic peripheral neuropathy.
Teverelix
go.drugbank.com/drugs/DB05624InvestigationalA synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.
International brands: Teverelix LAFaropenem medoxomil
go.drugbank.com/drugs/DB05659InvestigationalFaropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.
NV-52
go.drugbank.com/drugs/DB05673ExperimentalNV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.
FX06
go.drugbank.com/drugs/DB05685InvestigationalFX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.